Aptevo Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 7 million compared to USD 6.79 million a year ago. Basic loss per share from continuing operations was USD 1.45 compared to USD 2.15 a year ago. Basic loss per share was USD 1.43 compared to USD 2.1 a year ago. For the nine months, net loss was USD 22.19 million compared to USD 10.7 million a year ago. Basic loss per share from continuing operations was USD 4.94 compared to USD 7.35 a year ago. Basic loss per share was USD 4.8 compared to USD 3.31 a year ago.